Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04392154
Other study ID # 17789
Secondary ID 2020-001211-24J2
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date June 15, 2020
Est. completion date April 16, 2025

Study information

Verified date May 2024
Source Eli Lilly and Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.


Description:

Participants who have completed participation in a Dermira- or Lilly-sponsored lebrikizumab study (parent study), DRM06-AD04, DRM06-AD05, DRM06-AD06, DRM06-AD17 or DRM06- AD18, will be offered the opportunity to enroll in this study. Participants may either be blinded or not blinded, depending on their parent study assignment. This study will also be open to an additional approximately 100 participants in the United States (addendum) who have not completed participation in a Dermira- or Lilly-sponsored lebrikizumab study. Treatment will not be blinded. This study will also include an Addendum to extend the study treatment period by an additional 32 weeks and to add a treatment arm testing dosing every 8 weeks. This Addendum will apply to existing study participants in selected countries. Treatment will not be blinded.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1188
Est. completion date April 16, 2025
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria for participants coming from a parent study: Participants must meet all the following criteria to be eligible for this study: - Received treatment in a lebrikizumab study, NCT04146363, NCT04178967, NCT04250337, NCT04250350 and have adequately completed the study treatments and last patient visit of the parent trial. - For women of childbearing potential: agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method during the treatment period and for at least 18 weeks after the last dose of lebrikizumab or placebo. Exclusion Criteria for participants coming from a parent study: Participants meeting any of the criteria below will not be included in this study: - Participants who, during their participation in the parent trial, developed a serious adverse event (SAE) deemed related to lebrikizumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. * - Participants who, during their participation in the parent trial, developed an AE that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. * - Conditions in the previous parent study consistent with protocol-defined criteria for permanent study drug discontinuation, if deemed related to lebrikizumab or led to investigator - or sponsor-initiated withdrawal of participant from the study (e.g., non-compliance, inability to complete study assessments, etc.). * - Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study. Open-Label Addendum Inclusion Criteria: Participants must meet all the following criteria to be eligible for this study addendum: - Male or female adults and adolescents (=12 to <18 years of age and weighing =40 kilogram (kg). - Chronic AD (according to American Academy of Dermatology Consensus Criteria) that has been present for =1 year before screening. - Eczema Area and Severity Index (EASI) score =16 at baseline. - Investigator Global Assessment (IGA) score =3 (scale of 0 to 4) at baseline. - =10% body surface area (BSA) of AD involvement at baseline. - History of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable. Open-Label Addendum Exclusion Criteria: Participants meeting any of the criteria below will be excluded from this study addendum: - Have received a dose of lebrikizumab in any prior lebrikizumab clinical study. - History of anaphylaxis - Treatment with topical prescription moisturizers, corticosteroids, calcineurin inhibitors, or phosphodiesterase-4 inhibitors such as crisaborole within 1 week prior to baseline. - Treatment with any of the following agents within 4 weeks prior to the baseline. - Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, Interferon gamma (IFN-?), Janus kinase inhibitors, azathioprine, methotrexate, etc.) - Phototherapy and photochemotherapy (PUVA) for AD. - Treatment with the following prior to baseline: - Immunosuppressive/immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, IFN-?, Janus kinase inhibitors, azathioprine, methotrexate, etc.) - Phototherapy and photochemotherapy (PUVA) for AD. - Treatment with the following prior to baseline: - An investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer. - B Cell-depleting biologics, including rituximab, within 6 months. - Other Biologics within 5 half-lives (if known) or 8 weeks, whichever is longer. - Regular use (more than 2 uses per week) of a tanning booth/parlor within 4 weeks of baseline. - Treatment with a live (attenuated) vaccine within 12 weeks of the baseline or planned during the study. - Uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids, e.g., co-morbid severe uncontrolled asthma, (as defined by the investigator). - Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study. - Evidence of active acute or chronic hepatitis - History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening. - History of malignancy, including mycosis fungoides, within 5 years before screening, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks. Open-Label Extension Addendum Inclusion Criteria: Have completed Week 100 of Study KGAA and have not yet completed the safety follow-up visit for the main study. Open-Label Extension Addendum Exclusion Criteria: Have initiated treatment with a medication prohibited by Study KGAA before addendum baseline. This includes use of biologics for AD (for example, dupilumab and tralokinumab) during the safety follow-up period of Study KGAA.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Lebrikizumab
Subcutaneous injection

Locations

Country Name City State
Australia The Skin Centre Benowa Queensland
Australia Emeritus Research Camberwell Victoria
Australia Skin Health Institute Inc. Carlton Victoria
Australia The Skin Hospital Darlinghurst New South Wales
Australia Fremantle Dermatology Fremantle Western Australia
Australia Clinical Trials SA Pty Ltd Hectorville South Australia
Australia Premier Specialists Pty Ltd Kogarah New South Wales
Australia The St. George Hospital Kogarah New South Wales
Australia Sinclair Dermatology Melbourne Victoria
Australia Captain Stirling Medical Centre Nedlands
Australia Royal Children's Hospital Parkville Victoria
Australia The Royal Melbourne Hospital Parkville Victoria
Australia Woden Dermatology Phillip Australian Capital Territory
Australia University of the Sunshine Coast Clinical Trial Centre Sippy Downs Queensland
Australia Holdsworth House Medical Practice Sydney New South Wales
Australia Burswood Dermatology Victoria Park Western Australia
Australia Skin & Cancer Foundation Australia Westmead New South Wales
Australia Westmead Hospital Westmead New South Wales
Australia Veracity Clinical Research Pty Ltd Woolloongabba Queensland
Bulgaria DCC Sveti Georgi Haskovo
Bulgaria Alexandrovska University Hospital Sofia
Bulgaria Diagnostic and Consultation Center 14 Sofia
Bulgaria Euro Derma clinic Sofia
Bulgaria Medical centre Alitera-Med EOOD Sofia
Bulgaria Military Medical Academy Sofia
Canada CCA Medical Research Ajax Ontario
Canada Simcoderm Medical & Surgical Dermatology Centre Barrie Ontario
Canada Dermatology Research Institute Calgary Alberta
Canada Skin Health Cobourg Ontario
Canada Lynderm Research Inc. Markham Ontario
Canada International Dermatology Research Montreal Quebec
Canada International Dermatology Research Montréal Quebec
Canada North York Research Inc. North York Ontario
Canada The Centre for Clinical Trials, Inc Oakville Ontario
Canada Dermatology Ottawa Research Centre Ottawa Ontario
Canada Ottawa Allergy Research Corp Ottawa Ontario
Canada Skin Health Peterborough Ontario
Canada CARe Clinic Red Deer Alberta
Canada The Centre for Dermatology Richmond Hill Ontario
Canada Dr. Chih-ho Hong Medical Inc. Surrey British Columbia
Canada Enverus Medical Research Surrey British Columbia
Canada AvantDerm Toronto Ontario
Canada University of British Columbia Vancouver British Columbia
Canada K. Papp Clinical Research Waterloo Ontario
Canada Wiseman Dermatology Research Inc. Winnipeg Manitoba
Estonia Vahlberg & Pild OU Talinn
Estonia Kliiniliste uuringute Keskus OU Tartu
Estonia Tartu University Hospital Tartu
France CHU de Bordeaux Hop St ANDRE Bordeaux Gironde
France CHRU de Brest - Hôpital Morvan Brest
France CHU Dijonon Dijon
France CHD Vendee La Roche sur Yon
France Cabinet Médical Martigues
France Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu Nantes
France CHU de Nice Hopital de L'Archet Nice
France Hopital Saint Louis Paris
France Hopital Larrey Toulouse cedex 9
Germany Dermazentrum Augsburg Augsburg Bayern
Germany Praxis Dr. med. Virgil-Oreste Mihaescu Facharzt fr Dermatologie und STD Augsburg
Germany Fachklinik Bad Bentheim Bad Bentheim Niedersachsen
Germany Charité Campus Virchow-Klinikum Berlin
Germany ISA GmbH Berlin
Germany Praxis für Ganzheitliche Dermatologie im Ärztehaus Berlin
Germany Hautzentrum im Jahrhunderthaus Bochum Nordrhein-Westfalen
Germany Elbe Klinikum Buxtehude Buxtehude Niedersachsen
Germany Rosenpark Research GmbH Darmstadt Hessen
Germany Hautarztpraxis Dr. Gerlach Dresden Sachsen
Germany Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus - Klinik und Poliklinik fuer Dresden Saxony
Germany Klinikum der Johann Wolfgang Goethe-Universität Frankfurt Frankfurt Hesse
Germany Klinikum der Johann Wolfgang Goethe-Universität Frankfurt Frankfurt am Main Hessen
Germany SRH Wald-Klinikum Gera Gera Thüringen
Germany Dermatologikum Hamburg Hamburg
Germany TFS Trial Support Form GmbH Hamburg
Germany Studienzentrum Dr.Beate Schwarz Langenau Baden-Württemberg
Germany Universität Leipzig - Universitätsklinikum Leipzig Sachsen
Germany Velocity Clinical Research Leipzig GmbH Leipzig Saxony
Germany Universitätsklinikum Münster - Albert Schweitzer Campus Münster Nordrhein-Westfalen
Germany Klinische Forschung Osnabrück Osnabrück Lower Saxony
Germany Company for Medical Study & Service Selters GmbH Selters Rheinland-Pfalz
Germany Hautarztpraxis am Löwenmarkt Stuttgart Baden-Württemberg
Korea, Republic of Soon Chun Hyang University Bucheon Hospital Bucheon Gyeonggi-do
Korea, Republic of Pusan National University Hospital Busan Korea
Korea, Republic of Korea University Ansan Hospital Gyeonggi-do
Korea, Republic of Incheon St. Mary's Hospital Incheon
Korea, Republic of Asan Medical Center Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Chung-Ang University Hospital Seoul
Korea, Republic of Hallym University Kangnam Sacred Heart Hospital Seoul Seoul-teukbyeolsi [Seoul]
Korea, Republic of Hanyang University Medical Center Seoul Korea
Korea, Republic of Konkuk University Medical Center Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Korea, Republic of Ajou University Hospital Suwon Gyeonggi-do
Latvia Clinic of Dermatology and STD Riga
Latvia Health and Aesthetics LTD Riga
Latvia Health Center 4, Affiliate Diagnostic Center Riga
Latvia Latvian Dermatology Institute Riga
Latvia Smite Aija - Doctor Practice in Dermatology Venereology Talsi
Lithuania Hospital of Lithuanian University of Health Sciences Kauno klinikos Kaunas
Lithuania JSC "CD8 Alergology Clinic" Kaunas
Lithuania Children's Hospital, Affiliate of Vilnius University Hospital Santaros klinikos Vilnius
Lithuania JSC "Center for Diagnosis and Treatment of Allergic Diseases" Vilnius
Lithuania JSC Inlita (Santaros CTC) Vilnius
Lithuania Jsc Renmeda Vilnius
Lithuania Vilnius University Hospital Santaros Klinikos Vilnius
Mexico Derma Norte del Bajio Aguascalientes
Mexico Hospital Infantil de Mexico Federico Gomez Ciudad de Mexico Federal District
Mexico Grupo Clinico CATEI Sociedad Civil Guadalajara Jalisco
Mexico Cemdeicy S.C.P. Merida Yucatán
Mexico Clinica De Enfermedades Cronicas y Procedimientos Especiales Morelia Michoacan
Mexico Arke Estudios Clinicos S.A. de C.V. Veracruz
Poland Prywatna Praktyka Lekarska Gabinet Pediatryczno-Alergologiczny Anna Ploszczuk Bialystok
Poland Wojewodzki Szpital Zespolony Elblag
Poland Clinica Vitae Sp. z o.o. Gdansk Woj. Pomorskie
Poland Oddzial Dermatologii COPERNICUS Gdansk
Poland Centrum Badan Klinicznych PI-House sp. z o.o. Gdynia
Poland Zespol Naukowo - Leczniczy "Iwolang" Sp. z o.o. Iwonicz Zdroj Wojewodztwo Podkarpackie
Poland Centrum Medyczne Angelius Provita Katowice Slaskie
Poland Holsamed Katowice
Poland Holsamed Katowice
Poland Gabinet Dermatlogiczny. Beata Krecisz Kielce
Poland Diamond Clinic Krakow Malopolskie
Poland Grazyna Pulka Specjalistyczny Osrodek "ALL-MED" Krakow Malopolskie
Poland Dermoklinika Centrum Medyczne s.c. M. Kierstan J. Narbutt A. Lesiak Lodz Lodzkie
Poland Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Lublin
Poland Labderm s.c. Ossy Slaskie
Poland Centrum Alergologii Teresa Hofman Poznan
Poland Kliniczny Szpital Wojewodzki nr. 1 Klinika Dermatologii Rzeszow
Poland Laser Clinic Dermatologia Laserowa Medycyna Estetyczna Szczecin Zachodniopomorskie
Poland Twoja Przychodnia - Szczecinskie Centrum Medyczne Szczecin
Poland Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O. Tarnow
Poland Centrum Medyczne Evimed Warsaw Mazowieckie
Poland Centralny Szpital Kliniczny MSWiA Warszawa Mazowieckie
Poland Clinical Research Group Sp. z o.o. Warszawa
Poland High-Med Prywatny Gabinet Lekarski Warszawa
Poland Klinika Ambroziak Sp. Z.O.O. Warszawa
Poland MTZ Clinical Research Sp.z.o.o. Warszawa
Poland CityClinic Przychodnia Lekarsko-Psychologiczna Wroclaw
Poland dermMedica Sp. z o.o. Wroclaw Dolnoslaskie
Singapore Kk Women'S and Childrens Hospital Singapore
Singapore National Skin Centre NSC Singapore
Singapore National University Hospital Singapore Central Singapore
Singapore Singapore General Hospital Singapore
Spain Hospital General Universitario de Alicante Alicante
Spain Hospital Germans Trias i Pujol Badalona Catalunya [Cataluña]
Spain Hospital Clinic de Barcelona Barcelona
Spain Hospital de la Santa Creu i Sant Pau Barcelona
Spain Hospital Universitario Basurto Bilbao (Bizkaia)
Spain Hospital Sant Joan de Déu Esplugues de Llobregat Barcelona [Barcelona]
Spain Hospital Universitario Infanta Leonor-INTERNAL MED Madrid
Spain Hospital Universitario Virgen Macarena Sevilla
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung
Taiwan Taipei Medical University Shuang Ho Hospital New Taipei
Taiwan Kaohsiung Chang Gung Memorial Hospital Niaosong Kaohsiung City
Taiwan China Medical University Hospital Taichung
Taiwan Chung Shan Medical University Hospital Taichung
Taiwan National Taiwan University Hospital Taipei
Taiwan Chang Gung Memorial Hospital - Linkou Taoyuan City
Ukraine Municipal Healthcare Institution Kharkiv City Dermatoverenologic Dispensary N2 Kharkiv
Ukraine SE "Institute of Dermatology and Venerology of NAMS of Ukraine" Kharkiv
Ukraine Community Institution Zaporizhzhya Regional Dermatovenereology Clinical Hospital of Zaporizhzhya Regional Council Poshtova Square 2 Zaporizhzhya
Ukraine Rivne Regional Dermatology and Venereology Dispensary Rivne
Ukraine Treatment-diagnostic center PE "Asclepius" Uzhhorod
United States Georgia Pollens Clinical Research Centers, Inc Albany Georgia
United States Orange County Research Institute Anaheim California
United States Palmetto Clinical Trial Services, LLC Anderson South Carolina
United States Fivenson Dermatology Ann Arbor Michigan
United States Pinnacle Research Group, LLC Anniston Alabama
United States Arlington Research Center, Inc Arlington Texas
United States Oakland Dermatology Auburn Hills Michigan
United States Bakersfield Dermatology and Skin Cancer Medical Group Bakersfield California
United States Meridian Clinical Research Baton Rouge Louisiana
United States Great Lakes Research Group, Inc. Bay City Michigan
United States Bellaire Dermatology Associates Bellaire Texas
United States ActivMed Practices and Research Beverly Massachusetts
United States Wallace Medical Group, Inc. Beverly Hills California
United States Clinical Research Center of Alabama- Birmingham Birmingham Alabama
United States Brigham and Women's Hospital Boston Massachusetts
United States Tufts Medical Center Boston Massachusetts
United States Metro Boston Clinical Partners Brighton Massachusetts
United States Montefiore Medical Center Bronx New York
United States PI-Coor Clinical Research, LLC Burke Virginia
United States Hope Clinical Research, Inc. Canoga Park California
United States IMMUNOe International Research Centers Centennial Colorado
United States Clinical Research Center of the Carolinas Charleston South Carolina
United States Medical University of South Carolina Charleston South Carolina
United States OnSite Clinical Solutions Charlotte North Carolina
United States Northwestern University Chicago Illinois
United States Michigan Center for Research Company Clarkston Michigan
United States St. Francis Medical Institute Clearwater Florida
United States University Hospitals Case Medical Center Cleveland Ohio
United States Asthma and Allergy Associates, PC Colorado Springs Colorado
United States IACT Health - VHC Columbus Georgia
United States Florida Academic Centers Research and Education, LLC Coral Gables Florida
United States Pediatric Skin Research, LLC Coral Gables Florida
United States Central Connecticut Dermatology Cromwell Connecticut
United States Dermatology Treatment and Research Center Dallas Texas
United States Modern Research Associates Dallas Texas
United States Ohio Pediatric Research Association Dayton Ohio
United States Henry Ford Hospital Detroit Michigan
United States Austin Institute for Clinical Research Dripping Springs Texas
United States Psoriasis Treatment Center of Central New Jersey East Windsor New Jersey
United States California Dermatology & Clinical Research Institute Encinitas California
United States The Pennsylvania Centre for Dermatology, LLC Exton Pennsylvania
United States Clinical Physiology Associates Fort Myers Florida
United States Johnson Dermatology Fort Smith Arkansas
United States Innovate Research, LLC Fort Worth Texas
United States First OC Dermatology Fountain Valley California
United States MD Studies Fountain Valley California
United States Center For Dermatology Clinical Research, Inc. Fremont California
United States Associated Skin Care Specialists Fridley Minnesota
United States The University of Florida Health System Gainesville Florida
United States Rivergate Dermatology Clinical Research Center PL Goodlettsville Tennessee
United States Medication Management Greensboro North Carolina
United States Skin Laser and Surgery Specialists, a Division of Schweiger Dermatology Hackensack New Jersey
United States Direct Helpers Research Center Hialeah Florida
United States The Community Research of South Florida Hialeah Florida
United States Encore Medical Research Hollywood Florida
United States Burke Pharmaceutical Research Hot Springs Arkansas
United States Center for Clinical Studies Houston Texas
United States Encore Imaging & Medical Research Houston Texas
United States Suzanne Bruce and Associates, PA Houston Texas
United States Dawes Fretzin Clinical Research Group, LLC Indianapolis Indiana
United States Axon Clinical Research Inglewood California
United States Solutions Through Advanced Research Jacksonville Florida
United States Clinical Partners, LLC Johnston Rhode Island
United States Forest Hills Dermatology Group Kew Gardens New York
United States Sunwise Clinical Research Lafayette California
United States Avance Trials Laguna Niguel California
United States Cutis Wellness Dermatology Laredo Texas
United States Laredo Dermatology Associates P.A. Laredo Texas
United States JDR Dermatology Research Las Vegas Nevada
United States California Allergy and Asthma Medical Group + Research Center Los Angeles California
United States Dermatology Research Associates Los Angeles California
United States Keck School of Medicine University of Southern California Los Angeles California
United States LA Universal Research Center, INC Los Angeles California
United States Skin Sciences, PLLC Louisville Kentucky
United States Ablon Skin Institute and Research Center Manhattan Beach California
United States GSI Clinical Research, LLC Margate Florida
United States Marietta Dermatology Clinical Research Marietta Georgia
United States Crisor, LLC, Medford office Medford Oregon
United States Acevedo Clinical Research Associates Miami Florida
United States Community Research Foundation Inc Miami Florida
United States Florida Research Center, Inc Miami Florida
United States International Dermatology Research, Inc. Miami Florida
United States Miami Dermatology and Laser Research Miami Florida
United States Sanchez Clinical Research Inc Miami Florida
United States Vitae Research Center, LLC Miami Florida
United States Well Pharma Medical Research Corp. Miami Florida
United States C & R Research Services USA Miami Beach Florida
United States Wellness Clinical Research Miami Lakes Florida
United States University of Utah MidValley Dematology Murray Utah
United States Associated Skin Care Specialists New Brighton Minnesota
United States Tulane Univ School of Med New Orleans Louisiana
United States Icahn Sch of Med at Mt. Sinai New York New York
United States JUVA Skin & Laser Center New York New York
United States Sadick Research Group New York New York
United States Dermatology Clinical Trials Newport Beach California
United States Virginia Clinical Research, Inc. Norfolk Virginia
United States Sneeze, Wheeze, & Itch Associates LLC Normal Illinois
United States Arkansas Research Trials North Little Rock Arkansas
United States Tory Sullivan, MD PA North Miami Beach Florida
United States Lynn Health Science Institute Oklahoma City Oklahoma
United States Unity Clinical Research Oklahoma City Oklahoma
United States Advanced Dermatology of the Midlands Omaha Nebraska
United States Park Avenue Dermatology Orange Park Florida
United States Epiphany Dermatology of Kansas, LLC Overland Park Kansas
United States Cura Clinical Research Palmdale California
United States Riverchase Dermatology and Cosmetic Surgery Pembroke Pines Florida
United States Austin Institute for Clinical Research Pflugerville Texas
United States Paddington Testing Company Inc Philadelphia Pennsylvania
United States University of Pennsylvania Hospital Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States The Indiana Clinical Trials Center Plainfield Indiana
United States OHSU Center for Health and Healing Portland Oregon
United States Oregon Dermatology and Research Center Portland Oregon
United States Oregon Medical Research Center Portland Oregon
United States ALLCUTIS Research Portsmouth New Hampshire
United States MD Strategies Research Centers MDSRC Poway California
United States Beacon Clinical Research, LLC Quincy Massachusetts
United States Wake Research Associates Raleigh North Carolina
United States Dermatology and Skin Cancer Specialists, LLC Rockville Maryland
United States Northwest Arkansas Clinical Trials Center Rogers Arkansas
United States Arlington Dermatology Rolling Meadows Illinois
United States Integrative Skin Science and Research Sacramento California
United States Integrative Skin Science and Research Sacramento California
United States MediSearch Clinical Trials Saint Joseph Missouri
United States St Joseph Dermatology and Vein Clinic Saint Joseph Michigan
United States Central Dermatology PC Saint Louis Missouri
United States Velocity Clinical Research - Woseth Dermatology Salt Lake City Utah
United States Progressive Clinical Research San Antonio Texas
United States Texas Dermatology and Laser Specialists San Antonio Texas
United States Therapeutics Clinical Research San Diego California
United States University Clinical Trials San Diego California
United States University of California, San Diego/Rady Children's Hospital, San Diego - Pediatric & Adolescent Dermatology San Diego California
United States Synergy Dermatology San Francisco California
United States Care Access Research San Jose California
United States San Luis Dermatology & Laser Clinic San Luis Obispo California
United States Advanced Medical Research Sandy Springs Georgia
United States Southern California Dermatology, Inc. Santa Ana California
United States Georgia Skin & Cancer Clinic Savannah Georgia
United States Investigate MD Scottsdale Arizona
United States Dermatology Associates of Seattle Seattle Washington
United States Kansas Medical Clinic, an Elligo Health Research, Inc. Shawnee Mission Kansas
United States Northshore University Healthsystem Skokie Illinois
United States Premier Clinical Research Spokane Washington
United States Acclaim Dermatology PLLC Sugar Land Texas
United States DermDox Dermatology Centers Sugarloaf Pennsylvania
United States ForCare Clinical Research Tampa Florida
United States Olympian Clinical Research Tampa Florida
United States University of South Florida College of Medicine Tampa Florida
United States Kansas Medical Clinic Topeka Kansas
United States Central States Research Tulsa Oklahoma
United States Vital Prospects Clinical Research Institute, PC Tulsa Oklahoma
United States Peak Research LLC Upper Saint Clair Pennsylvania
United States AAPRI Clinical Research Institute Warwick Rhode Island
United States George Washington University Medical Center Washington District of Columbia
United States Medical Faculty Associates, Inc. Washington District of Columbia
United States Advanced Asthma and Allergy Watertown New York
United States Center for Clinical Studies Webster Texas
United States Dundee Dermatology West Dundee Illinois
United States Jordan Valley Dermatology Center West Jordan Utah
United States Wilmington Dermatology Center Wilmington North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Eli Lilly and Company Dermira, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Canada,  Estonia,  France,  Germany,  Korea, Republic of,  Latvia,  Lithuania,  Mexico,  Poland,  Singapore,  Spain,  Taiwan,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit Baseline to Week 100
Secondary Percentage of Participants with a Response of Investigator Global Assessment (IGA) Score 0 or 1 Baseline to Week 100
Secondary Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) from Baseline of Parent Study Baseline to Week 100
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2